Comparing HLX17 vs. Keytruda for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests if a new drug called HLX17 works as well as the approved drug Keytruda for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see which one better controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-squamous non-small cell lung cancer that has spread and cannot be removed by surgery or treated with radiation.
- Your cancer must not have certain genetic changes (EGFR, ALK, or ROS1).
- You must not have received any previous treatment for your advanced lung cancer.
- You must have at least one tumor that can be measured on scans.
- You must be well enough to do daily activities (ECOG score 0 or 1).
- Your organs must be working well enough to handle the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug, MB12, works as well as Keytruda for people with advanced non-small cell lung cancer who haven't had treatment yet. It aims to offer a more affordable option.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial tests a new combination of two immunotherapy drugs (HLX07 and serplulimab) plus chemotherapy versus standard treatments (pembrolizumab or serplulimab plus chemo) for people with advanced squamous non-small cell lung cancer who haven't had treatment yet. The goal is to see if the new combination works better.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial compares a new medicine called QL2107 to the approved drug Keytruda in people with non-small cell lung cancer (NSCLC) that has been removed completely by surgery and treated with chemotherapy. The goal is to see if QL2107 works similarly to Keytruda in preventing the cancer from coming back.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.